Drug Trial Radar · NCT06625242
A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Oct 22, 2024
Primary completion
Jan 21, 2026
Study completion Feb 25, 2026
Sponsor
- Lead sponsor
- Eisai Korea Inc.Eisai
- Sponsor type
- Industry
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the percentage of participants achieving an American College of Rheumatology (ACR) 20 percent (%) Improvement (ACR20) response at Week 12 of the administration of the investigational product.
Conditions
- Rheumatoid Arthritis
Interventions
Filgotinib MaleateDrug
Administered as oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving ACR20 Response at Week 12Time frame: At Week 12
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Eisai site #11
Anyang-si, South Korea
Eisai site #01
Busan, South Korea
Eisai site #09
Daegu, South Korea
Eisai site #12
Daegu, South Korea
Eisai site #06
Daejeon, South Korea
Eisai site #15
Guri-si, South Korea
Eisai site #02
Gwangju, South Korea
Eisai site #13
Incheon, South Korea
Eisai site #03
Seoul, South Korea
Eisai site #04
Seoul, South Korea
Eisai site #05
Seoul, South Korea
Eisai site #07
Seoul, South Korea
Eisai site #08
Seoul, South Korea
Eisai site #10
Seoul, South Korea
Eisai site #14
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.